What the evidence shows at a glance

By 12 months, published clinical research consistently records a rise of roughly 30 points in patient-reported knee function scores for people treated with ChondroFiller — moving from a pre-treatment average of around 48 on the subjective IKDC scale to approximately 80. At that level, most patients report comfortable everyday activity and recreational sport without significant restriction.

On MRI, structural repair follows a parallel trajectory: MOCART scores — a radiologist's measure of defect fill and tissue integration — climb from approximately 65 at four weeks post-injection to between 81 and 84 at 12 months, consistent with more than 80% defect fill and sound border integration with surrounding cartilage.

These findings are not drawn from a single source. A 2016 prospective randomised multicentre trial and an independent 2024 knee cohort reached the same conclusions separately, both achieving statistical significance at the three-, six-, and twelve-month marks. The sections below examine what each score means in practice, how the improvement timeline unfolds, and what the evidence suggests about durability through 36 months.

What an IKDC score means in everyday terms

The IKDC questionnaire is filled in by patients themselves — not by a clinician interpreting a scan — and covers 18 questions about how the joint feels day to day: pain, swelling, stiffness, the ability to climb stairs, and whether recreational or competitive sport is possible.

A pre-treatment score of around 48 sits in the moderate-to-significant limitation band. Patients at this level commonly report avoiding stairs when possible, cutting back on sport, and noticing the knee during routine activities such as walking on uneven ground. A score of approximately 80, reached consistently by 12 months in published ChondroFiller series, corresponds to comfortable everyday activity and recreational sport without meaningful restriction — the joint no longer dominates ordinary decisions about how to move.

The size of that rise matters as much as the direction. At roughly 30 points, it exceeds the established minimum clinically important difference of 16.7 points — the threshold below which researchers consider a change indistinguishable from measurement noise. A gain of this magnitude signals that the improvement is real and felt in daily life, not merely an artefact of the scoring system.

Equally reassuring is the timing. Data from Simeonov's 2024 knee cohort (n=17, mean age 31) showed no statistically significant difference between six-month and twelve-month IKDC scores (p>0.05), indicating that functional recovery largely consolidates within the first six months rather than accumulating slowly over years.

What MOCART scores reveal on MRI

Radiologists score ChondroFiller-treated joints on the MOCART scale by examining four structural questions from the MRI: how completely the defect cavity has filled, how smoothly the repair tissue aligns with the surrounding surface, how cleanly it has integrated at the edges where new tissue meets old, and whether the repaired area shows a signal pattern on the scan that looks closer to healthy cartilage or closer to scar tissue. The result is a single figure between 0 and 100.

As the evidence overview noted, treated knees typically score around 65 at four weeks — a scaffold that has filled the defect and begun integrating but is not yet fully mature. By 12 months, published knee series place the mean at 81–84. In structural terms, a score above 80 corresponds to more than 80% of the defect filled, a smooth surface contour flush with adjacent cartilage, and sound border integration: in plain language, tissue that has grown into the defect and largely blended with what surrounds it rather than sitting on top of it.

The clinical weight of reaching that level is quantified by a 2025 study of 86 tibiofemoral cartilage repair patients, which identified a MOCART 2.0 score of 60 or above at one year as an independent predictor of favourable patient-reported outcomes — specifically, improvements exceeding the clinically important threshold on Lysholm and KOOS symptom scores. The ROC cut-off proved stable across a ±5-point adjustment range, lending the 60-point benchmark practical durability rather than statistical fragility. ChondroFiller's reported 12-month means of 81–84 land comfortably above it, suggesting the structural repair achieved in the first year provides a sound platform for the functional gains patients report.

Why IKDC and MOCART measure different things — and why both matter

Feeling significantly better and achieving full tissue repair are two separate biological processes — and they tend to move at different speeds. The IKDC questionnaire captures patient experience; MOCART captures what a radiologist reads on an MRI. Both run from 0 to 100, but a high score on one does not reliably predict a high score on the other.

Research from osteochondral lesion repair illustrates this independence directly. A systematic analysis of postoperative data found correlations between MOCART readings and patient-reported outcomes as low as r≤0.22 — weak enough that one score cannot substitute for the other in clinical monitoring. A patient's knee may feel markedly better while structural maturation on MRI is still progressing; conversely, well-integrated repair tissue on a scan is not a guarantee of immediate functional improvement.

That asymmetry is precisely why clinicians track both. IKDC answers whether treatment has changed how the patient lives; MOCART answers whether the scaffold has produced durable tissue in the defect cavity. They complement rather than duplicate each other, and neither is more 'correct' — they simply ask different questions. Taken together, they offer the clearest available window into how a focal cartilage defect is genuinely responding: not just on one dimension, but across both the structural and the experiential.

Evidence at 36 months and what it does — and does not — confirm

The most extensive long-term ChondroFiller dataset comes from a prospective hip cohort of 26 patients with acetabular cartilage lesions larger than 2 cm², tracked across three to five years. At serial assessments throughout that window, 17 of 21 evaluable patients — 81% — achieved good-to-excellent results with MRI-confirmed cartilage healing. As evidence that collagen scaffold repair can prove durable over a multi-year horizon, the finding is genuinely encouraging.

It is, however, hip data rather than knee data, and should not be read as a direct transfer. Biomechanical loading, defect geometry, and the joint environment differ enough between the hip and the tibiofemoral or patellofemoral spaces that outcomes in one do not reliably forecast outcomes in the other.

For the knee specifically, no adequately powered randomised controlled trial has yet completed follow-up at 24 or 36 months. Published knee series — including the 2016 multicenter trial and the 2024 Simeonov cohort — demonstrate robust, statistically significant improvements across the first year, but formal tracking of those gains into the second and third year remains an open research question. Most available data come from smaller prospective or manufacturer-linked cohorts rather than independent long-term trials.

The honest position is that 12-month knee evidence is consistent and clinically meaningful; data specifically following knee patients beyond that point are still accumulating. That is a gap in the published record, not a warning sign about the treatment — but it is a distinction worth drawing clearly.

Who is most likely to benefit from this treatment

The evidence points in one direction: ChondroFiller performs well for a specific patient profile and poorly outside it, making selection the dominant modifier of outcome — more influential than any technical factor in the injection process itself.

The clearest predictor of a good result is a focal, contained cartilage defect — typically under 2–3 cm² — sitting within an otherwise reasonably healthy joint. Published series consistently associate this profile with the functional gains described in earlier sections. Younger, active patients form the bulk of the strongest-performing cohorts, including the 2024 Simeonov knee series, in which the mean age was 31.

The clearest predictor of a poor result is an existing osteoarthritis grade. In the hip cohort data, patients with Tönnis 2–3 disease — indicating moderate-to-severe generalised joint degeneration — consistently achieved poor outcomes. ChondroFiller is engineered for a localised area of damage in an otherwise healthy joint, not for wear distributed across the whole articular surface. Where degeneration is generalised, the scaffold has no stable environment into which to integrate.

A 2024 biomechanical in-vitro study adds one practical post-treatment consideration: the collagen hydrogel carries initial mechanical instability under cyclic loading, and the authors recommend delaying full weight-bearing until stable defect filling is established. This is a rehabilitation protocol detail rather than a deterrent, but patients should expect a protected loading period in the weeks following injection.

Of all these factors, osteoarthritis grade is the most actionable — and the most decisive. It is confirmed by imaging before a consultation is complete, and in the published literature that single finding, more reliably than defect size or patient age alone, determines whether the joint environment fits the treatment criteria.

1. [1] Implantation of ChondroFiller Liquid® as a scaffold for chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: cohort study 12–60 months. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Correlation of MOCART Score with Patient-Reported Outcome Scores after Ankle Osteochondral Lesion Repair. (2022). https://doi.org/10.1177/2473011421s00733 https://doi.org/10.1177/2473011421s00733
5. [5] MOCART 2.0 score ≥60 at 1 year predicts favourable outcomes after tibiofemoral cartilage repair. (2025). https://doi.org/10.1002/ksa.70086 https://doi.org/10.1002/ksa.70086
6. [6] Influence of cartilage defects and collagen gel on intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z